Evotec Extends Ongoing Collaboration With CHDI Foundation

Evotec Extends Ongoing Collaboration With CHDI Foundation

  *Collaboration aims to accelerate development of drugs that slow the
    progression of Huntington's disease (HD)

  *Evotec eligible to receive up to USD 41 million

HAMBURG, Germany, OXFORD, UnitedKingdom,LOS ANGELES, Oct. 29, 2012 (GLOBE
NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that CHDI
Foundation, Inc. (CHDI), a privately-funded not-for-profit research
organisation dedicated to developing therapies for Huntington's disease (HD),
has extended its collaboration with Evotec until the end of 2015. This
contract extension could be worth up to USD 41 million in research payments
for Evotec.

The collaboration takes full advantage of Evotec's integrated drug discovery
platform and its proficiency in neurological research, including its expertise
in medicinal chemistry, in vitro and in vivo pharmacology, and compound
management.

Evotec and CHDI entered into this alliance in March 2006, and since then the
collaborative relationship has grown significantly. The extension of this
collaboration further validates Evotec's broad expertise in CNS drug discovery
and development.

"We are delighted that CHDI, an organisation dedicated solely to the quest to
discover novel drugs against Huntington's disease, continues to work in
partnership with Evotec," said Dr Mario Polywka, Chief Operating Officer of
Evotec. "This collaboration is an excellent example of how companies,
including foundations such as CHDI, can access Evotec's platform suite of
technologies, capabilities and strong disease biology expertise, to drive
their drug discovery efforts."

"CHDI partners with a global network of investigators from the academic,
biopharmaceutical, and service sectors to execute our drug discovery and
development efforts," said Dr Robert Pacifici, Chief Scientific Officer at
CHDI. "Evotec represents one of our largest and longest standing relationships
with a contract research organisation. We are delighted that, with the renewal
of our contract, CHDI and Evotec will be able to continue our productive
interactions and drive our therapeutic programs forward."

About Huntington's disease

Huntington's disease is a familial disease caused by a mutation in the
huntingtin gene. Each child of a parent with the mutation in the huntingtin
gene has a 50-50 chance of inheriting the mutation. As a result of carrying
the mutation, an individual's brain cells fail and die leading to cognitive
and physical impairments that, over the course of the disease, significantly
impair the individual's quality of life and ultimately cause death. Symptoms
of Huntington's disease, which generally develop in midlife and become
progressively more debilitating as time passes, can also develop in infancy or
old age. Once overt symptoms start, patients live for about 15 to 20 years.
One person in 10,000 is believed to carry a mutation in the huntingtin gene.
There is currently no way to delay the onset of symptoms or slow the
progression of Huntington's disease.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech,
Medimmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. In addition,
the Company has existing development partnerships and product candidates both
in clinical and preclinical development. These include a strategic alliance
with Roche for the development of subtype-selective NMDA receptor antagonists
for use in treatment-resistant depression as well as other partnerships with
Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of
diabetes. For additional information please go to www.evotec.com.

Forward-Looking Statements: Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Dr Mario Polywka
         Chief Operating Officer
         +44.(0)1235.44 16 76
         +44.(0)7771.95 41 90 Fax
         mario.polywka@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Deutschland)